



## LJMU Research Online

**Panizzolo, FA, Maiorana, AJ, Naylor, LH, Dembo, LG, Lloyd, DG, Green, DJ and Rubenson, J**

**Muscle size explains low passive skeletal muscle force in heart failure patients.**

<http://researchonline.ljmu.ac.uk/id/eprint/4760/>

### Article

**Citation** (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

**Panizzolo, FA, Maiorana, AJ, Naylor, LH, Dembo, LG, Lloyd, DG, Green, DJ and Rubenson, J (2016) Muscle size explains low passive skeletal muscle force in heart failure patients. PeerJ, 4. ISSN 2167-8359**

LJMU has developed [LJMU Research Online](#) for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact [researchonline@ljmu.ac.uk](mailto:researchonline@ljmu.ac.uk)

<http://researchonline.ljmu.ac.uk/>

# Muscle size, not quality, explains low passive skeletal muscle force in heart failure patients

Fausto A. Panizzolo<sup>1</sup>, Andrew J. Maiorana<sup>2,3</sup>, Louise H. Naylor<sup>1</sup>, Lawrence Dembo<sup>4</sup>, David G. Lloyd<sup>1,5</sup>, Daniel J. Green<sup>1,6</sup>, and Jonas Rubenson<sup>1,7</sup>

<sup>1</sup>The School of Sport Science, Exercise and Health, The University of Western Australia, Crawley, WA, Australia.

<sup>2</sup>Advanced Heart Failure and Cardiac Transplant Service, Royal Perth Hospital, Perth, WA, Australia.

<sup>3</sup>School of Physiotherapy and Exercise Science, Curtin University, Perth, WA, Australia.

<sup>4</sup>Envision Medical Imaging, Perth, Western Australia, Australia.

<sup>5</sup>Centre for Musculoskeletal Research, Griffith Health Institute, Griffith University, Gold Coast, QLD, Australia.

<sup>6</sup>Research Institute for Sport and Exercise Science, Liverpool John Moores University, Liverpool, United Kingdom.

<sup>7</sup>Biomechanics Laboratory, Department of Kinesiology, The Pennsylvania State University, University Park, PA, USA.

**Corresponding author:** Dr. Fausto A. Panizzolo

School of Engineering and Applied Sciences, Wyss Institute for Biologically Inspired Engineering, Harvard University, 60 Oxford st, Cambridge, MA, United States.

Email: [fpanizzolo@seas.harvard.edu](mailto:fpanizzolo@seas.harvard.edu)

26 **ABSTRACT**

27 **Background.** Impaired skeletal muscle has been linked to the compromised exercise capacity  
28 characterizing chronic heart failure (CHF). However, how passive skeletal muscle force is affected  
29 in CHF is not clear. Understanding passive force characteristics in CHF can help further elucidate the  
30 extent to which altered contractile properties and architecture affect muscle and locomotor function.  
31 Therefore, the aim of this study was to investigate passive force in a single muscle for which non-  
32 invasive measures of muscle size are possible, the soleus (SOL), both in CHF patients and age- and  
33 physical activity-matched control participants.

34 **Methods.** Soleus muscle force and size were obtained by means of a novel approach combining  
35 experimental data (dynamometry, electromyography, ultrasound imaging) with a musculoskeletal  
36 model.

37 **Results.** We found reduced passive SOL forces (~30%) (at equivalent levels of muscle stretch) in  
38 CHF *vs.* healthy individuals. This difference was eliminated when force was normalized by  
39 physiological cross sectional area, indicating that reduced force output may be most strongly  
40 associated with muscle size. Nevertheless, passive force was significantly higher in CHF at a given  
41 absolute muscle length and likely explained by the shorter optimal muscle lengths measured in CHF  
42 compared to the control participants. This later factor may lead to altered performance of the SOL in  
43 functional tasks such gait.

44 **Discussion.** These findings suggest exercise rehabilitation targeting muscle hypertrophy, and for the  
45 calf muscles, exercise that promotes muscle lengthening.

46

47

48

49

50



## 52 INTRODUCTION

53 Growing evidence suggests that deficiencies in the skeletal muscle contributes to the limited  
54 functional capacity that characterizes chronic heart failure (CHF) and to the progression of the  
55 disease. For example, it is apparent that patients with CHF have a reduction in muscle size (*Mancini*  
56 *et al., 1992; Minotti et al., 1993; Anker et al., 1999; Fülster et al., 2013*) and strength (as determined  
57 by net joint moments) in the lower limbs (*Magnusson et al., 1994; Chua et al., 1995; Harrington et*  
58 *al., 1997; Sunnerhagen et al., 1998; Toth et al., 2006; Toth et al., 2010; Panizzolo et al., 2015*)  
59 compared to healthy age-matched individuals, and that these reductions are related to aerobic exercise  
60 capacity (*Volterrani et al., 1994; Harrington et al., 1997; Panizzolo et al., 2015*). It is still not clear,  
61 however, if the reduction in muscle and functional capacity are associated primarily with reduced  
62 muscle size that is known to occur in CHF (*Mancini et al., 1992; Fülster et al., 2013; Panizzolo et*  
63 *al., 2015*) or if size-independent characteristics- muscle quality- is an important determinant. Indeed,  
64 several studies that have measured both voluntary strength and muscle size in the quadriceps suggest  
65 that muscle size alone does not account for the loss of strength (*Harrington et al., 1997; Toth et al.,*  
66 *2006; Toth et al., 2010*). Resolving whether muscle size or quality is more closely linked to muscle  
67 function can prove important for guiding rehabilitation strategies in CHF.

68 Measurements of passive muscle forces and how they are related to muscle architecture can  
69 provide important information for understanding the mechanisms behind the alterations in skeletal  
70 muscle function associated with CHF. In particular, they can shed further light on whether motor  
71 deficits are related primarily to reductions in muscle size and the extent to which altered contractile  
72 properties and architecture affect *in vivo* function at a whole muscle level without introducing  
73 variability arising from voluntary and/or twitch contractions (*Princivero et al., 2000; Oskuei et al.,*  
74 *2003*). Passive forces are also functionally relevant as they influence normal (*Silder, Heiderscheit &*  
75 *Thelen, 2008*) and pathological (*Geertsen et al., 2015*) gait mechanics.

76 Our understanding of how passive skeletal muscle force is affected in CHF is currently  
77 unclear. Passive forces in cardiac muscle are altered in CHF (*Van der Velden, 2011*), as well as in  
78 diaphragm skeletal muscle (*Van Hees et al., 2010*). Surprisingly, as far as we are aware, only one  
79 study (*Van Hees et al., 2010*) has investigated passive forces in appendicular skeletal muscle in CHF  
80 and it has been conducted in a mouse model. This study reported unaltered passive forces in the soleus  
81 (SOL) muscle of CHF-affected mice, compared to a control group, when taking into consideration  
82 muscle size.

83 The aim of this study was to investigate the passive forces in the SOL muscle of CHF patients and  
84 age- and physical activity-matched control participants, as well as the relationship between muscle  
85 architecture [physiological cross sectional area (PCSA), muscle length, pennation angle] and passive  
86 force. The SOL was selected because it permits an estimation of passive force in a single muscle  
87 (*Rubenson et al., 2012; Tian et al., 2012*). Furthermore, SOL has been identified as a primary muscle  
88 in which muscle loss occurs in CHF (*Panizzolo et al., 2015; Green et al., 2016*) and its size is strongly  
89 correlated with the reduced exercise capacity present in CHF (*Panizzolo et al., 2015*) (more so than  
90 the gastrocnemius synergist) and thus is a muscle of choice for muscle-specific analysis. We  
91 hypothesized that there would be a reduction in passive force in CHF patients, compared to a healthy  
92 population. We further hypothesized that passive force would be similar after normalizing for the  
93 muscle PCSA, thus attributing any alteration to muscle size.

94

## 95 **MATERIALS AND METHODS**

### 96 **Participants**

97 Patients with CHF and age- and physical activity-matched control participants who were free from  
98 other musculoskeletal disorders and lower limb musculoskeletal injuries were recruited for this study.  
99 The CHF group included 12 participants (7 men, 5 women) in the class II-IV of the New York Heart  
100 Association (NYHA) classification with an ejection fraction of  $30.5 \pm 9.6\%$ . (For anthropometric

101 characteristics and exclusion criteria see Table 1). The control group was composed of 12 healthy  
102 participants recruited from the local community (8 men, 4 women). The CHF group underwent  
103 regular exercise activity 2-3 times per week for ~ 1 hour per session (treadmill walking and resistance  
104 weight training) as part of their standard patient care. The control participants underwent similar  
105 levels of weekly exercise. All participants read and signed an informed consent prior to participating  
106 in the study and all of the procedures were approved by the Human Research Ethics Committee at  
107 The University of Western Australia (approval ID: RA/4/1/2533) and Royal Perth Hospital (approval  
108 ID: 2011/019).

109

#### 110 **Passive force estimates**

111 The procedures used to estimate passive and active SOL forces were similar to those adopted  
112 previously, with the exception that passive force was measured during continuous joint rotation  
113 (*Rubenson et al., 2012*). Passive moments were recorded with the participants sitting upright with  
114 their right foot and ankle positioned in a dynamometer (Biodex M3, Shirley, NY, USA) and with the  
115 knee positioned at 120° of flexion (0° knee fully extended) to mitigate the force contribution of the  
116 gastrocnemius muscles (*Maganaris, 2001*). The net passive ankle joint moment ( $M_p$ ) was computed  
117 by subtracting the moment generated by the Biodex rig and the weight of the foot (*Rubenson et al.,*  
118 *2012*); the weight of the foot was expressed as a percentage of body mass. The  $M_p$  over a joint's range  
119 of motion passes through zero at an angle that approximates where passive muscle forces reach zero  
120 (*Silder et al., 2007*) (Figure 1). Moment data recorded by the dynamometer were filtered using 4<sup>th</sup>-  
121 order zero-lag 2 Hz low-pass Butterworth filter (MATLAB, The MathWorks Inc., USA). To detect  
122 the inflexion point in  $M_p$  where net dorsiflexion and plantarflexion moment converge on zero we first  
123 fitted the joint angle vs.  $M_p$  data with a 5<sup>th</sup>-order polynomial based on visual inspection of the data

124 and subsequently computed the first order derivative of this function (MATLAB, The MathWorks  
125 Inc., USA) (Figure 1).

126 In some instances the inflexion point was slightly above or below zero moment ( $<1.5$  Nm or  
127  $\sim 7\%$  of the peak passive moment). This can occur if the weight of the leg transmits a small moment  
128 about the Biodex axis (i.e. small misalignment of ankle center of rotation) or if the moment predicted  
129 from weight of the foot has small errors. In these cases the passive moment data was corrected for  
130 the offset. Contribution from synergist muscles are minimal at the joint postures adopted (*Maganaris,*  
131 *2001; Silder et al. 2007; Rubenson et al., 2012*). Passive force estimates from subject-specific scaled  
132 OpenSim models (version 2.0.2) further indicated that passive force from synergist muscles were  
133 minimal at the recorded knee and ankle postures.

134 The method described above does not account for passive moments arising from joint  
135 articulations and skin, but these are minimal compared to the passive moments arising from passive  
136 force in the Achilles tendon (*Costa et al., 2006*). In passive trials electromyography (EMG) from the  
137 tibialis anterior (TA), the medial and lateral gastrocnemius muscles (MG, LG, respectively) and the  
138 SOL were recorded (Noraxon wireless system, Scottsdale, AZ, USA, 2000 Hz) to ensure the muscles  
139 crossing the ankle remained inactive. For each trial, real-time root-mean-square (RMS) waves of the  
140 muscles' activity were computed from the EMG signals (incorporating DC offset; Spike2 V7  
141 software; Cambridge Electronic Design, Cambridge, UK) (*Rubenson et al. 2012*). Soleus fascicle  
142 lengths and pennation angle were recorded using dynamic B-mode ultrasound (Telemed, EchoBlaster  
143 128, Lithuania; 25 Hz capture rate; 7.5 MHz 60 mm linear array probe) following the placement and  
144 image analysis procedures outlined previously (*Rubenson et al., 2012; Panizzolo et al., 2013*).  
145 Simultaneous measurements of ankle joint flexion/extension angles were made using a portable 3D  
146 motion capture system (Optitrack, Corvallis, Oregon, US, 100 Hz). The net joint moment, EMG,  
147 ultrasound images and joint angles were recorded synchronously (Micro1401-3; Cambridge  
148 Electronic Design, Cambridge, UK; 2000 Hz) as the ankle was cycled through its full range of motion  
149 (the most plantarflexed and most dorsiflexed position tolerated by the participant) at a constant speed

150 of 5°/s over three consecutive cycles. Three initial warm-up cycles were performed prior the recording  
151 of any measurements. The SOL passive force ( $F_{p_{SOL}}$ ) was computed continuously throughout the joint  
152 range of motion as the joint underwent dorsiflexion. Passive force was calculated as per (*Rubenson*  
153 *et al.*, 2012) using the following equation:

$$154 \quad F_{p_{SOL}} = \frac{M_p}{r \cdot \cos \theta} \quad (1)$$

155 Where  $r$  represents the Achilles moment arm data and  $\theta$  the SOL pennation angle. Participant-specific  
156 Achilles moment arm data were established experimentally on a separate testing day, following the  
157 method described previously in (*Manal, Cowder & Buchanan, 2010*). In this method B-model  
158 ultrasound (Telemed, Echo Blaster 128, Lithuania) was used to capture Achilles tendon images in the  
159 sagittal plane from the participants while their foot was cycled passively at an angular velocity of 5°/s  
160 across its range of motion in a Biodex dynamometer (M3, Biodex, Shirley, NY, USA). The ultrasound  
161 probe (7.5 MHz, 60 mm field of view, linear array probe, 50 Hz capture rate) was placed  
162 longitudinally above the Achilles tendon using a stand-off gel pad (Aquaflex, Parker, NJ, USA).  
163 Simultaneously, the trajectories of two retro-reflective markers mounted on the ultrasound probe were  
164 recorded by means of a 3D motion capture system (Optitrack, Corvallis, Oregon, US, 100 Hz).  
165 Additional anatomical landmarks (first metatarsal, calcaneus, medial malleoli and knee medial  
166 condyle) were tracked to calculate the ankle flexion/extension joint angle. A 2D customized graphical  
167 interface was developed in Matlab to display both the ultrasound images and the ultrasound probe  
168 and the medial malleoli markers in the same coordinate system. The line of action of the Achilles  
169 tendon was digitized in this common coordinate system and the moment arm was computed as the  
170 perpendicular distance between the tendon line of action and the medial malleoli, which was used as  
171 an estimate of the ankle joint center. This procedure was performed at 10 ankle joint angles that  
172 spanned the joint's range of motion. A 10-point moment arm-joint angle curve was obtained for each  
173 participant by using a polynomial fit of the moment arm-joint angle data.

174 We defined the fascicle slack length ( $L_{slack}$ ) as the length where passive SOL forces are first  
175 generated, estimated as the point where the net passive dorsiflexion and plantarflexion moments  
176 converge on zero, and the fascicle length at the maximum tolerated dorsiflexion angle as the maximal  
177 fascicle length ( $L_{max}$ ). Absolute and normalized passive SOL force-length (F-L) curves were  
178 established for each participant. Absolute passive F-L curves used the measured  $F_{pSOL}$  in Newtons  
179 and fascicle lengths ( $L$ ) in mm. Normalized passive F-L curves were created by dividing each  
180 participant  $F_{pSOL}$  by their SOL PCSA (Equation 1) and by dividing  $L$  by  $L_{slack}$  (normalized length  
181 referred to here as  $L_{norm}$ ). The PCSA was determined from underwater 3D ultrasound scans  
182 (Telemed, EchoBlaster 128, Lithuania; Stradwin, Medical Imaging Research Group, Cambridge  
183 University Engineering Department, UK) following (Panizzolo *et al.*, 2015). To enable the  
184 comparison of absolute  $F_{pSOL}$  between groups,  $F_{pSOL}$  was determined at a percent fascicle stretch of  
185 0%, 20%, 40%, 60%, 80% and 100% of the maximum fascicle stretch, where percent fascicle stretch  
186 was defined as  $((L - L_{slack}) \div (L_{max} - L_{slack})) * 100$ . The same procedure was done to compare  
187 passive moment data over both angle and muscle length ranges. Passive fascicle stiffness was  
188 computed for each participant as the slope of the absolute F-L curves between  $L_{slack}$  and 40% stretch  
189 ( $k_1$ ) and between 60% - 100% stretch ( $k_2$ ). In order to compare the normalized passive F-L curves  
190 we evaluated the normalized  $F_{pSOL}$  at a set of  $L_{norm}$  between 1.0 and 1.4 (i.e. strain of 0 - 40%) using  
191 intervals of 0.05. A peak  $L_{norm}$  was set to 1.4 as this represented the average maximum  $L_{norm}$  that  
192 the participants achieved at their end range of ankle dorsiflexion. The normalized  $F_{pSOL}$  was  
193 computed for each individual for the interval described above by fitting the normalized  $F_{pSOL}$  and  
194  $L_{norm}$  data using a 1<sup>st</sup>-order exponential equation (Gollapudi & Lin, 2009). In some circumstances  
195 where the set range exceeded the experimental  $L_{norm}$  the normalized  $F_{pSOL}$  values were extrapolated  
196 from the exponential equation. Stiffness was computed between  $L_{norm}$  of 1.0 and 1.2 ( $k_{1norm}$ ) and  
197 1.2 and 1.4 ( $k_{2norm}$ ).

198

199 **Active forces estimates**

200 As an ancillary comparison of the muscle lengths, we also analyzed peak active muscle forces at  
201 different ankle angles (and thus muscle lengths) to generate an active force-length relationship. The  
202 optimal muscle length coinciding with maximal peak active force ( $L_0$ ) is known to correspond well  
203 with  $L_{slack}$ , both in human and non-human studies (Azizi & Roberts, 2010), including the human SOL  
204 (Rubenson *et al.*, 2012) and can thus serve as an additional test for differences in fascicle lengths  
205 between groups. The protocol used in this study to obtain predictions of moments and force generated  
206 by the SOL (as well as the moments and force generated by synergist muscles and by the co-  
207 contraction of dorsiflexor muscles) expands on the procedures established in (Rubenson *et al.*, 2012).  
208 It uses a combination of experimental net moment measurements from dynamometry, ultrasound  
209 fascicle imaging, electromyography and a scaled participant-specific musculoskeletal model in  
210 OpenSim 2.0.2 (Delp *et al.*, 2007). Predictions were performed with the knee in a flexed position  
211 ( $>120^\circ$ ) and over a range of ankle angles from  $\sim -30^\circ$  dorsiflexion to  $30^\circ$  plantarflexion (the ankle  
212 range of motion varied between individuals). The muscle length that corresponded with the maximal  
213 peak active force was designated as  $L_0$ .

214 First, a generic lower-limb model (Arnold *et al.*, 2010) was scaled using each participant's  
215 joint axes and centers determined via motion capture data (8-camera VICON MX motion capture  
216 system, Oxford Metrics, UK; 100 Hz) from participants in a standing posture as well as dynamic joint  
217 motions (Besier *et al.*, 2003). From these trials, an inverse kinematics algorithm was run on the  
218 position of 26 retroreflective spherical markers placed on anatomical landmarks and on functionally  
219 determined joint centers (Besier *et al.*, 2003), that minimized the distance between the OpenSim  
220 model markers and the retroreflective and the functionally determined markers.

221 The moment generated by the plantarflexors ( $M_{plant}$ ) during the maximal voluntary isometric  
222 plantarflexion contractions ( $MVC_{plant}$ ) was calculated as:

223 
$$M_{plant} = M_{peak} - \Delta M_p + M_{dorsi} \quad (2)$$

224 where  $M_{peak}$  is the peak net ankle joint moment (calculated as the difference between the Biodex  
225 recorded moment during  $MVC_{plant}$  and the moment at rest),  $\Delta M_p$  represents the difference in the  
226 estimated passive SOL moment during the  $MVC_{plant}$  and the passive SOL moment at rest prior to the  
227 contraction, and  $M_{dorsi}$  is the moment generated by the co-contraction of the dorsiflexors muscles.  
228  $\Delta M_p$  was calculated as:

$$229 \quad \Delta M_p = (F_{p_{SOL}}^{contr} * \cos \theta^{contr} * r^{contr}) - (F_{p_{SOL}}^{rest} * \cos \theta^{rest} * r^{rest}) \quad (3)$$

230 where  $F_{p_{SOL}}$  was obtained for both the fascicle length at the  $MVC_{plant}$  and the fascicle length during  
231 the rest period just prior to contraction using a linear interpolation of the passive F-L relationship  
232 (*rest* and *contr* superscripts designate rest or  $MVC_{plant}$ , respectively).  $r^{contr}$  was estimated by  
233 increasing the value predicted from the experimental Achilles moment arm- joint angle equation  
234 (described above) by 20% to take in account the increase in moment arm distance reported during  
235  $MVC_{plant}$  with respect to length at rest (Maganaris et al., 1998).

236 The  $M_{dorsi}$  was predicted by the participant-specific OpenSim model. First, the OpenSim  
237 maximal isometric forces of all the dorsiflexors (tibialis anterior, extensor digitorum longus, extensor  
238 hallucis longus, peroneus tertius) were adjusted by the same percentage increase or decrease so that  
239 the predicted model's peak isometric dorsiflexion moment at 100% activation ( $MVC_{dorsi}$ ) matched  
240 that of the participant's experimental maximum  $M_{dorsi}$  recorded in the Biodex dynamometer at 10°  
241 plantarflexion, the angle that corresponds approximately to optimal dorsiflexion moments (Silder et  
242 al., 2007). The  $MVC_{dorsi}$  were performed only at this joint angle to reduce the total numbers of  
243 contractions performed and time spent in the experimental protocol by each participant. This was an  
244 important consideration because of the general high fatigability of CHF patients. In this procedure,  
245 the OpenSim model was positioned to match the participant's optically recorded ankle and knee joint  
246 posture. In subsequent measurements of  $MVC_{plant}$  the  $M_{dorsi}$  was predicted by the OpenSim model  
247 by prescribing an activation to all of the dorsiflexors equal to the ratio of the TA's peak EMG (linear

248 envelope) during the  $MVC_{plant}$  to its peak EMG (linear envelope) from the  $MVC_{dorsi}$  trial; i.e. this  
249 assumed the same activation level for all dorsiflexors.

250 To take into account the contribution of synergist muscles we predicted the relative percentage  
251 contribution of each plantarflexors muscle to the total plantarflexor moment in OpenSim ( $M_{Syn}$ ) by  
252 prescribing the recorded ankle and knee angles and 100% activation of all plantarflexor muscles  
253 (peroneus longus, peroneus brevis, flexor hallucis, tibialis posterior, flexor digitorum, MG, LG and  
254 SOL). The percent contribution of the OpenSim SOL to the total predicted moment was applied to  
255 the experimental  $MVC_{plant}$  to define the moment generated by the participant's SOL ( $M_{aSOL}$ ). Lastly,  
256 peak voluntary active SOL force production ( $F_{aSOL}$ ) was calculated as:

$$257 \quad F_{aSOL} = \frac{M_{aSOL}}{r^{contr} * \cos \theta^{contr}} \quad (4)$$

258 These active force trials were performed only by the participants that were able to tolerate a  
259 prolonged protocol (n = 7 and n = 8, for control and CHF participants, respectively).

260

## 261 **Statistical analysis**

262 Differences in the absolute (non-normalized) passive moment-angle, moment-length and F-L curves  
263 were assessed by testing if  $F_{pSOL}$  were different between groups (CHF and control), and if passive  
264 joint angles and/or fascicle lengths were affected, by using a two-way (CHF/control) repeated  
265 measures (0% 20%, 40%, 60%, 80% and 100% of angular excursion or muscle stretch, respectively)  
266 ANOVA, with Bonferroni *post hoc* tests. Similar two-way repeated measures ANOVAs were also  
267 performed on the normalized F-L curves using the  $L_{norm}$  set range (1.0 - 1.4). A two-tailed unpaired  
268 Student's t-test with significance level of  $p < 0.05$  was used to determine significant differences in  
269 the  $L_{slack}$ ,  $L_{max}$ , the maximal fascicle stretch, and  $L_0$ , as well as in the passive fascicle stiffness  
270 ( $k_1$ ,  $k_2$ ,  $k_{1norm}$  and  $k_{2norm}$ ) between the groups. Statistical analysis was performed in SPSS (IBM,  
271 Statistics 21, USA).

272

## 273 RESULTS

274 No main effect of group was found in the joint angle between the CHF and control groups ( $p = 0.42$ )  
275 (Figure 2). A main effect of group on net passive ankle joint moment was found ( $p = 0.014$ ) with  
276 lower passive moment in the CHF group compared to the control group at equivalent levels of angular  
277 excursion and fascicle stretch, although no statistically significant interaction effect was found ( $p =$   
278  $0.398$ ) between group and moment (Figure 2).

279 A main effect of group on absolute  $F_{p_{SOL}}$  (N) was found ( $p = 0.027$ ) with lower absolute  
280  $F_{p_{SOL}}$  in the CHF group compared to the control group at equivalent levels of fascicle stretch, although  
281 no statistically significant interaction effect was found ( $p = 0.11$ ) between group and level of stretch.  
282 No differences were found in  $k_1$  and  $k_2$  between the groups ( $p = 0.32$ ; ES = 0.51 and  $p = 0.85$ ; ES =  
283 0.09) (Figure 3a). The  $L_{max}$  was significantly shorter in the CHF group compared to the control group  
284 ( $p = 0.046$ ; ES = 0.96), although no statistically significant differences were found in  $L_{slack}$  ( $p = 0.11$ ;  
285 ES = 0.76) and in the maximal fascicle stretch ( $L_{max} - L_{slack}$ ) ( $p = 0.34$ ; ES = 0.44) (Table 2) or  
286 maximal fascicle strain ( $p = 0.7$ ; ES = 0.09).

287 No main effect was found in the PCSA-normalized  $F_{p_{SOL}}$  (N cm<sup>-2</sup>) between the CHF and  
288 control groups when using the  $L_{norm}$  strain range of 1.0-1.4 ( $p = 0.46$ ) (Figure 3b), nor was there an  
289 interaction effect between the PCSA-normalized  $F_{p_{SOL}}$  and normalized lengths ( $p = 0.52$ ).  
290 Normalized passive fascicle stiffness ( $k_{1norm}$  and  $k_{2norm}$ ) were not significantly different between  
291 the groups ( $p = 0.42$ ; ES = 0.44 and  $p = 0.54$ ; ES = 0.33) (Figure 3b).

292  $L_0$  determined from the active force-length data was significantly shorter (~22%) in the CHF  
293 group compared to the control group ( $p = 0.039$ ; ES = 0.96) (Table 2). The voluntary forces were  
294 derived at a range of ankle joint angles, and therefore over a range of fascicle lengths. The maximal  
295  $F_{a_{SOL}}$  and corresponding  $L_0$  occurred at approximately 10° dorsiflexion. The  $F_{a_{SOL}}$  at both shorter and  
296 longer fascicle lengths relative to  $L_0$  decreased, characteristic of the muscle force-length relationship

297 (Figure 4).  $L_0$  was not significantly different from  $L_{slack}$  in either the control or CHF groups ( $p =$   
298 0.33 and  $p = 0.39$ , respectively; Table 2).

299

## 300 **DISCUSSION**

301 The present study provides, to the best of our knowledge, the first estimate of *in vivo* passive human  
302 skeletal muscle force-length properties in CHF. As predicted, higher absolute  $M_p$  and  $F_{p\ SOL}$  were  
303 produced in the control group for a given amount of muscle stretch (Figure 2, 3). Also in agreement  
304 with our hypothesis, passive force is not different after normalizing by muscle PCSA, nor is passive  
305 muscle stiffness affected, indicating that muscle size rather than intrinsic muscle properties is a major  
306 factor influencing passive force and stiffness in CHF SOL muscle. This finding stands in contrast to  
307 previous work reporting stiffer cardiac muscle due to alterations in the titin structure (Wu, 2002) or  
308 decreased passive force of the diaphragm, due to titin loss (Van Hees et al., 2010) in CHF. On the  
309 other hand, our results do corroborate data from passive skeletal muscle properties in the mouse SOL,  
310 in which passive forces from CHF-affected animals were likewise not altered after normalizing to  
311 muscle cross sectional area (Van Hees et al., 2010).

312 It was surprising, however, that for a given absolute muscle length, passive force was  
313 significantly higher in CHF SOL compared to the control group. This unexpected finding stems from  
314 the fact that over the same ankle range of motion the passive muscle lengths are shorter in CHF  
315 patients, in particular at maximal stretch (Figure 2, 3). The result is that for the same absolute muscle  
316 length (above  $L_{slack}$ ) the CHF muscle has undergone greater strain, thus generating greater force in  
317 titin and other passive load bearing muscle components. Previous experimental studies (Azizi &  
318 Roberts, 2010; Winters et al., 2011; Rubenson et al., 2012) have shown agreement between the onset  
319 of passive force generation ( $L_{slack}$ ) and  $L_0$  (optimal length for active force production). The estimate  
320 of  $L_0$  in the present study was similar to  $L_{slack}$  for both groups and significantly ( $p < 0.05$ ) shorter in  
321 the CHF group (Table 2). The shorter  $L_{slack}$  and  $L_0$  in CHF patients indicates that the SOL has

322 undergone a loss of in-series sarcomere numbers, a contributing factor to the reduced muscle size  
323 (*Panizzolo et al., 2015*). It was also surprising that, despite their shorter muscle fascicles, CHF  
324 patients underwent the same ankle range of motion and a similar SOL muscle strain across this range  
325 of motion (Figure 2, Table 2). The Achilles moment arms were similar between the control and CHF  
326 group suggesting that greater Achilles strain might explain the similarity in joint and muscle  
327 excursions. This is partially supported by the smaller tendon cross sectional area reported in CHF  
328 (*Panizzolo et al., 2015*).

329

### 330 **Functional implications**

331 Our results are consistent with the observation that muscle size dictates functional deficits in CHF  
332 (*Magnusson et al., 1994*). Exercise that promotes hypertrophy should therefore be a focus for  
333 restoring functional capacity in leg muscles. Exercise prescription for CHF is becoming  
334 commonplace, but programs that include specifically designed lower limb resistance training might  
335 be especially promising (*Maiorana et al., 2000*).

336 Our results also offer insight into the gait mechanics of CHF patients (*Panizzolo et al., 2014*).  
337 The combination of the shorter SOL muscle fascicles in CHF patients and their greater dorsiflexion  
338 during mid-stance of gait (*Panizzolo et al., 2014*) may cause significantly greater SOL strain. This  
339 might lead to the muscle operating on to the descending limb of the F-L curve where large passive  
340 forces develop (*Rassier, MacIntosh & Herzog., 1999; Rubenson et al., 2012*). In this scenario CHF  
341 patients would rely more on their passive forces to support the plantarflexion moment during walking,  
342 which has the benefit of reducing metabolically expensive active force development. This may help  
343 explain why CHF patients rely proportionately more on their ankle for powering walking as speed  
344 and metabolic demand increases (*Panizzolo et al., 2014*). However, whilst metabolically  
345 advantageous, this mechanism might lead to greater lengthening-induced muscle damage. The  
346 muscle's F-L operating range depends on multiple factors, including tendon stiffness, and a detailed  
347 understanding will require further *in vivo* analyses.

348

349 **CONCLUSION**

350 This work suggests that a primary factor leading to lower passive forces in the SOL is likely a  
351 reduction in muscle size. However, shorter muscle fascicles in CHF results in greater passive forces  
352 for a given absolute muscle length, and might be linked to changes in CHF gait (*Panizzolo et al.,*  
353 *2014*). Exercise that promotes calf muscle hypertrophy and serial sarcomerogenesis may prove  
354 particularly beneficial in CHF patients.

355

356 **ACKNOWLEDGEMENTS**

357 This work was supported by a Grant-in-Aid (G09P 4469) from the National Heart Foundation of  
358 Australia to J.R., D.J.G., A.J.M. and D.G.L., and a thesis dissertation grant from the International  
359 Society of Biomechanics to F.A.P. The authors would like to acknowledge Ms. Kirsty McDonald and  
360 Ms. Maddison Jones for their help during data collection, and all of the participants who volunteered  
361 for this study.

362

363 **REFERENCES**

364 Anker SD, Ponikowski PP, Clark AL, Leyva F, Rauchhaus M, Kemp M, Teixeira MM, Hellewell  
365 PG, Hooper J, Poole-Wilson PA, Coats AJ. Cytokines and neurohormones relating to body  
366 composition alterations in the wasting syndrome of chronic heart failure. *Eur Heart J.* 1999; 20:  
367 683–693.

368

369 Arnold EM, Ward SR, Lieber RL, Delp SL. A model of the lower limb for analysis of human  
370 movement. *Ann Biomed Eng.* 2010; 38: 269-279.

371

372 Azizi E, Roberts TJ. Muscle performance during frog jumping: influence of elasticity on muscle  
373 operating lengths. *Proc Biol Sci.* 2010; 277: 1523–1530.

374

375 Besier TF, Sturnieks DL, Alderson JA, Lloyd DG. Repeatability of gait data using a functional  
376 hip joint centre and a mean helical knee axis. *J Biomech.* 2003; 36: 1159-1168.

377

378 Chua TP, Anker SD, Harrington D, Coats AJ. Inspiratory muscle strength is a determinant of  
379 maximum oxygen consumption in chronic heart failure. *Br Heart J.* 1995; 74: 381–385.

380

381 Costa ML, Logan K, Heylings D, Donell ST, Tucker K. The effect of Achilles tendon lengthening  
382 on ankle dorsiflexion: a cadaver study. *Foot Ankle Int.* 2006; 27: 414-417.

383

384 Delp SL, Anderson FC, Arnold AS, Loan P, Habib A, John CT, Guendelman E, Thelen DG.  
385 OpenSim: open-source software to create and analyze dynamic simulations of movement. *IEEE*  
386 *Trans Biomed Eng.* 2007; 54: 1940–1950.

387

388 Fülster S, Tacke M, Sandek A, Ebner N, Tschöpe C, Doehner W, Anker SD, von Haehling S.  
389 Muscle wasting in patients with chronic heart failure: results from the studies investigating co-  
390 morbidities aggravating heart failure (SICA-HF). *Eur Heart J.* 2013; 34: 512–519.

391

392 Geertsens SS, Kirk H, Lorentzen J, Jorsal M, Johansson CB, Nielsen JB. Impaired gait function in  
393 adults with cerebral palsy is associated with reduced rapid force generation and increased passive  
394 stiffness. *Clin Neurophysiol.* 2015; 126: 2320-2329.

395

396 Gollapudi SK, Lin DC. Experimental determination of sarcomere force-length relationship in  
397 type-I human skeletal muscle fibers. *J Biomech.* 2009; 42: 2011-2016.

398 Green DJ, Panizzolo FA, Lloyd DG, Rubenson J, Maiorana AJ. Soleus muscle as a surrogate for  
399 health status in human heart failure. *Exerc Sport Sci Rev.* 2016; 44:45-50.  
400

401 Harrington D, Anker SD, Chua TP, Webb-Peploe KM, Ponikowski PP, Poole-Wilson PA, Coats  
402 AJ. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. *J Am  
403 Coll Cardiol.* 1997; 30: 1758–1764.  
404

405 Maganaris CN, Baltzopoulos V, Sargeant AJ. Changes in Achilles tendon moment arm from rest  
406 to maximum isometric plantarflexion: in vivo observations in man. *J Physiol.* 1998; 510: 977–  
407 985.  
408

409 Maganaris CN. Force-length characteristics of in vivo human skeletal muscle. *Acta Physiol  
410 Scand.* 2001; 172: 279–285.  
411

412 Magnusson G, Isberg B, Karlberg KE, Sylvén C. Skeletal muscle strength and endurance in  
413 chronic congestive heart failure secondary to idiopathic dilated cardiomyopathy. *Am J Cardiol.*  
414 1994; 73: 307–309.  
415

416 Maiorana A, O’Driscoll G, Cheetham C, Collis J, Goodman C, Rankin S, Taylor R, Green D.  
417 Combined aerobic and resistance exercise training improves functional capacity and strength in  
418 CHF. *J Appl Physiol.* 2000; 88: 1565–1570.  
419

420 Manal K, Cowder JD, Buchanan TS. A hybrid method for computing achilles tendon moment  
421 arm using ultrasound and motion analysis. *J Appl Biomech.* 2010; 26: 224–228.

422 Mancini DM, Walter G, Reichek N, Lenkinski R, McCully KK, Mullen JL, Wilson JR.  
423 Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in  
424 heart failure. *Circulation*. 1992; 85: 1364–1373.

425

426 Minotti JR, Pillay P, Oka R, Wells L, Christoph I, Massie BM. Skeletal muscle size: relationship  
427 to muscle function in heart failure. *J Appl Physiol*. 1993; 75: 373–381.

428

429 Oskouei MA, Van Mazijk BC, Schuiling MH, Herzog W. Variability in the interpolated twitch  
430 torque for maximal and submaximal voluntary contractions. *J Appl Physiol*. 2003; 95: 1648-1655.

431

432 Panizzolo FA, Green DJ, Lloyd DG, Maiorana AJ, Rubenson J. Soleus fascicle length changes  
433 are conserved between young and old adults at their preferred walking speed. *Gait Posture*. 2013;  
434 38: 764–769.

435

436 Panizzolo FA, Maiorana AJ, Naylor LH, Dembo L, Lloyd DG, Green DJ, Rubenson J. Gait  
437 analysis in chronic heart failure: the calf as a locus of impaired walking capacity. *J Biomech*.  
438 2014; 47: 3719-3725.

439

440 Panizzolo FA, Maiorana AJ, Naylor LH, Lichtwark GA, Dembo L, Lloyd DG, Green DJ,  
441 Rubenson J. Is the soleus a sentinel muscle for impaired exercise capacity in heart failure? *Med*  
442 *Sci Sport Exerc*. 2015; 47: 498-508.

443

444 Pincivero DM, Green RC, Mark JD, Campy RM. Gender and muscle differences in EMG  
445 amplitude and median frequency, and variability during maximal voluntary contractions of the  
446 quadriceps femoris. *J Electromyography Kines*. 2000; 10: 189-196.

447       Rassier DE, MacIntosh BR, Herzog W. Length dependence of active force production in skeletal  
448       muscle. *J Appl Physiol.* 1999; 86: 1445-1457.

449

450       Rubenson J, Pires NJ, Loi HO, Pinniger GJ, Shannon DG. On the ascent: the soleus operating  
451       length is conserved to the ascending limb of the force-length curve across gait mechanics in  
452       humans. *J Exp Biol.* 2012; 215: 3539–3551.

453

454       Silder A, Whittington B, Heiderscheit B, Thelen DG. Identification of passive elastic joint  
455       moment-angle relationships in the lower extremity. *J Biomech.* 2007; 40: 2628–2635.

456

457       Silder A, Heiderscheit B, Thelen DG. Active and passive contributions to joint kinetics during  
458       walking in older adults. *J Biomech.* 2008; 41: 1520–1527.

459

460       Sunnerhagen KS, Cider Å, Schaufelberger M, Hedberg M, Grimby G. 1998. Muscular  
461       performance in heart failure. *J Card Fail.* 1998; 4: 97–104.

462

463       Tian M, Herbert RD, Hoang P, Gandevia SC, Bilston LE. Myofascial force transmission between  
464       the human soleus and gastrocnemius muscles during passive knee motion. *J Appl Physiol.* 2012;  
465       113: 517-523.

466

467       Toth MJ, Ades PA, Tischler MD, Tracy RP, LeWinter MM. Immune activation is associated with  
468       reduced skeletal muscle mass and physical function in chronic heart failure. *Int J Cardiol.* 2006;  
469       109: 179–187.

470

471 Toth MJ, Shaw AO, Miller MS, VanBuren P, LeWinter MM, Maughan DW, Ades PA. Reduced  
472 knee extensor function in heart failure is not explained by inactivity. *Int J Cardiol.* 2010; 143:  
473 276–282.

474

475 Van der Velden J. Diastolic myofilament dysfunction in the failing human heart. *Pflugers Arch.*  
476 2011; 462: 155–163.

477

478 Van Hees HW, Ottenheijm CA, Granzier HL, Dekhuijzen PN, Heunks LM. Heart failure  
479 decreases passive tension generation of rat diaphragm fibers. *Int J Cardiol.* 2010; 141: 275–283.

480

481 Volterrani M, Clark AL, Ludman PF, Swan JW, Adamopoulos S, Piepoli M, Coats AJ. Predictors  
482 of exercise capacity in chronic heart failure. *Eur Heart J.* 1994; 15, 801–809.

483

484 Winters TM, Takahashi M, Lieber RL, Ward, S.R. Whole muscle length-tension relationships are  
485 accurately modeled as scaled sarcomeres in rabbit hindlimb muscles. *J Biomech.* 2011; 44: 109–  
486 115.

487

488 Wu Y. Changes in titin isoform expression in pacing-induced cardiac failure give rise to  
489 increased passive muscle stiffness. *Circulation.* 2002; 106: 1384–1389.